|Articles|June 1, 2002
Phaco advance minimizes risk of endothelial cell loss
Rockville Centre, NY-Sonolase, a new mode of phacoemulsification power produced by the WhiteStar software for the Sovereign system (Advanced Medical Optics Inc. [AMO], the new entity formed in the recent Allergan spin-off), reduces the amount of energy expended in the eye and minimizes corneal endothelial cell loss.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
2
Last year in glaucoma at EnVision Summit 2025
3
Metformin use associated with reduced incidence of intermediate AMD
4
NeuroOp Guru: Understanding optic disc cupping after optic neuritis
5
























